Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
group_3_presentation_1_-_parkinsons [2019/02/01 18:52] gilli1 [Diagnosis] |
group_3_presentation_1_-_parkinsons [2019/02/01 19:04] (current) gilli1 [Drugs and Medication] |
||
|---|---|---|---|
| Line 9: | Line 9: | ||
| ===== History ===== | ===== History ===== | ||
| - | <box 20% round right | > {{ :essay.png?200|}} </box| Figure 2: The first page of the essay written by James Parkinson.> | + | <box 18% round right | > {{ :essay.png?200|}} </box| Figure 2: The first page of the essay written by James Parkinson.> |
| Traditionally, descriptions of PD can be found as early as 1000 BC for Indian texts, in addition to those within ancient Chinese sources.<sup>[2]</sup> PD was initially described by James Parkinson in 1817 through this work in “Essay on the shaking palsy”.<sup>[3]</sup> This was originally thought to be a movement disorder with three fundamental signs: bradykinesia, rigidity, and tremors.<sup>[3]</sup> Parkinson at that time described the disease as: “involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported; with a propensity to bend the trunk forward, and to pass from a walking to a running pace: the senses and intellects being uninjured”.<sup>[2]</sup> With time, postural changes and instability were included as a fourth fundamental sign.<sup>[4]</sup> | Traditionally, descriptions of PD can be found as early as 1000 BC for Indian texts, in addition to those within ancient Chinese sources.<sup>[2]</sup> PD was initially described by James Parkinson in 1817 through this work in “Essay on the shaking palsy”.<sup>[3]</sup> This was originally thought to be a movement disorder with three fundamental signs: bradykinesia, rigidity, and tremors.<sup>[3]</sup> Parkinson at that time described the disease as: “involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported; with a propensity to bend the trunk forward, and to pass from a walking to a running pace: the senses and intellects being uninjured”.<sup>[2]</sup> With time, postural changes and instability were included as a fourth fundamental sign.<sup>[4]</sup> | ||
| Line 79: | Line 79: | ||
| ===== Drugs and Medication ===== | ===== Drugs and Medication ===== | ||
| - | Currently there is no cure for PD but various drugs and medication can provide relief from the symptoms. Over the recent years, extensive research has been conducted allowing for significant results in treatments for PD. Although there are numerous medications available, the use of these drugs are dependent on the disease stage and the age of onset. The main groups of drugs used for treating PD, especially for the coordination of movement, are: levodopa, MAO-B inhibitors, and dopamine agonists. | + | Currently there is no cure for PD but various drugs and medication can provide relief from the symptoms. Over the recent years, extensive research has been conducted allowing for significant results in treatments for PD. Although there are numerous medications available, the use of these drugs are dependent on the disease stage and the age of onset. The main groups of drugs used for treating PD, especially for the coordination of movement, are: levodopa, dopamine agonists, and MAO-B inhibitors. |
| <box 20% round right | > {{ :screen_shot_2019-01-31_at_8.08.40_pm.png?200|}} </box| Figure 7: Dopaminergic synapse in the substantia nigra with levodopa.> | <box 20% round right | > {{ :screen_shot_2019-01-31_at_8.08.40_pm.png?200|}} </box| Figure 7: Dopaminergic synapse in the substantia nigra with levodopa.> | ||
| ==== Levodopa ==== | ==== Levodopa ==== | ||
| Line 111: | Line 111: | ||
| ==== AFQ056 ==== | ==== AFQ056 ==== | ||
| - | This is selective antagonist of the mGluR5 receptor which can help mediate symptoms of dyskinesia. This drug is particularly effective at reducing the amount of dyskinesia as a direct result of levodopa.<sup>[31]</sup> This drug had statically significant impact on patients that were on levodopa treatment.<sup>[31]</sup> This drug is too given in conjecture with traditional treatments and can dramatically reduce certain symptoms. It is still early in the testing process, but has shown excellent progression thus far. | + | This is selective antagonist of the mGluR5 receptor which can help mediate symptoms of dyskinesia. This drug is particularly effective at reducing the amount of dyskinesia as a direct result of levodopa.<sup>[31]</sup> This drug had statically significant impact on patients that were on levodopa treatment.<sup>[31]</sup> This drug is given in conjecture with traditional treatments and can dramatically reduce certain symptoms. It is still early in the testing process, but has shown excellent progression thus far. |
| ===== Conclusion ===== | ===== Conclusion ===== | ||
| - | PD is one the most common neurodegenerative diseases, directly impacting many globally. A decrease in the production of dopamine triggers various symptoms, slowly affecting the body. Though there is no test or cure for PD, There are future therapies researchers are working on to help those affected by Parkinson’s disease. | + | PD is one the most common neurodegenerative diseases, directly impacting many globally. A decrease in the production of dopamine triggers various symptoms, slowly affecting the body. Though there is no test or cure for PD, there are future therapies researchers are working on to help those affected by Parkinson’s disease. |
| With what we know, there is still more work that needs to be done. Researchers are continuing to understand the progression of PD and how best to overcome it. | With what we know, there is still more work that needs to be done. Researchers are continuing to understand the progression of PD and how best to overcome it. | ||
